FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children

FDA Labeling Mandate on Febrile Seizure Risks

In a significant update to vaccine safety protocols, the U.S. Food and Drug Administration (FDA) has required pediatric influenza vaccines to include warnings about an elevated risk of febrile seizure influenza vaccine adverse events. The FDA issued notifications on January 9, 2026, to biologics license holders for products like FluMist (MedImmune, LLC), Fluzone (Sanofi), Fluarix (GlaxoSmithKline), Flulaval (ID Biomedical Corporation of Quebec), Afluria (Seqirus Pty Ltd.), and Flucelvax (Seqirus, Inc.), under section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act (FDCA). These require adding new safety details on febrile seizure influenza vaccine risks for children aged 6 months to 4 years after standard-dose trivalent (2024-2025 formula) and quadrivalent (2023-2024 formula) vaccinations, based on postmarketing studies from the Biologics Effectiveness and Safety System (BEST). The updates highlight a causal link, with risks peaking in the first 24 hours post-vaccination. For comprehensive details on these safety communications, refer to official FDA records.

Spike in Febrile Seizures After Vaccination

Postmarketing data from the 2023-2024 and 2024-2025 flu seasons show a clear uptick in febrile seizures among young children soon after standard-dose influenza shots, drawn from three commercial insurance claims databases. Self-controlled case series (SCCS) analyses reveal an incidence rate ratio (IRR) of 1.97 [95% confidence interval (CI): 1.09, 3.54] for quadrivalent vaccines, equating to 21.2 extra febrile seizure cases per million doses, and an IRR of 2.94 [95% CI: 1.72, 5.01] for trivalent vaccines, with 44.2 excess cases per million in one dataset. This points to a 97% and 194% relative risk rise, respectively, in the 0-1 day window versus the 8-63 day baseline. The temporal pattern supports causality, driving FDA’s push for labeling changes in vaccines for kids under 5, including expanded warnings and precautions.

Robust Surveillance Methods Underpin Risks

The FDA’s directives lean on strong observational tools from the BEST system, pulling real-world U.S. insurance claims data. The core SCCS method reduces bias through individual-level comparisons, pitting febrile seizure rates in the 0-1 day post-vaccination window against the 8-63 day control for children 6 months to 4 years across two seasons. Analyses use this to gauge attributable risks, with significant confidence intervals. Under FDCA section 505-1(b)(3), the FDA deems this “new safety information,” requiring label updates through prior approval supplements, changes being effected, or rebuttals—noncompliance could lead to misbranding charges under section 502(z) and penalties.

Health Economics Ripple Effects

Updated labels may boost provider training and parent discussions, possibly dipping vaccination rates among cautious families and impacting herd immunity plus costs from flu illnesses; still, the modest risks (21.2-44.2 cases per million) pale next to flu’s toll. In reimbursement landscapes, bodies like the Centers for Medicare & Medicaid Services (CMS) might weave in this postmarketing data for formulary choices, spurring measures like post-shot checks without hiking prices. Ultimately, real-world evidence sharpens HEOR frameworks, safeguarding value-driven access amid pediatric concerns.